{"product_id":"droncef-500mg-1g-injection-ceftriaxone-pharma-services-group","title":"DRONCEF 500mg \u0026 1g Injection (Ceftriaxone) | Pharma Services Group","description":"\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eDRONCEF Injection contains Ceftriaxone, a third-generation cephalosporin antibiotic available in 500mg and 1g strengths for the treatment of susceptible bacterial infections.\u003c\/strong\u003e The supplied packaging identifies DRONCEF as \u003cstrong\u003eCeftriaxone 1g Injection\u003c\/strong\u003e and describes it as a \u003cstrong\u003eThird Generation Cephalosporin Antibiotic\u003c\/strong\u003e for IV use. Drug Regulatory Authority of Pakistan (DRAP) records identify DRONCEF 500mg Injection IV as containing \u003cstrong\u003eCeftriaxone (as sodium)\u003c\/strong\u003e and list Seraph Pharmaceutical as the company.\u003c\/p\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eCeftriaxone 500mg and 1g injections\u003c\/strong\u003e are prescription antibiotics used for a wide range of bacterial infections when injectable antibiotic therapy is clinically indicated. Ceftriaxone works by interfering with bacterial cell-wall synthesis, helping eliminate susceptible bacteria. The appropriate strength, route, dose and duration depend on the type and severity of infection, patient age, weight, kidney and liver function and the treating physician's clinical judgment. DRAP documentation also confirms the \u003cstrong\u003eDroncef 1g IV\u003c\/strong\u003e presentation manufactured by Seraph Pharmaceuticals.\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003eAvailable Strengths\u003c\/h2\u003e\r\\n\u003ctable\u003e\r\\n\u003ctbody\u003e\r\\n\u003ctr\u003e\r\\n\u003cth\u003eProduct Variant\u003c\/th\u003e\r\\n\u003cth\u003eActive Ingredient\u003c\/th\u003e\r\\n\u003cth\u003eStrength\u003c\/th\u003e\r\\n\u003cth\u003eRoute\u003c\/th\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003e\u003cstrong\u003eDRONCEF 500mg Injection\u003c\/strong\u003e\u003c\/td\u003e\r\\n\u003ctd\u003eCeftriaxone (as sodium)\u003c\/td\u003e\r\\n\u003ctd\u003e500mg\u003c\/td\u003e\r\\n\u003ctd\u003eIV\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003e\u003cstrong\u003eDRONCEF 1g Injection\u003c\/strong\u003e\u003c\/td\u003e\r\\n\u003ctd\u003eCeftriaxone (as sodium)\u003c\/td\u003e\r\\n\u003ctd\u003e1g\u003c\/td\u003e\r\\n\u003ctd\u003eIV\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003c\/tbody\u003e\r\\n\u003c\/table\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eThe supplied 1g packaging states \u003cstrong\u003e“For I.V. Use.”\u003c\/strong\u003e Current Pakistani regulatory records list Droncef 500mg IV and Droncef 1g IV presentations.\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003eKey Benefits\u003c\/h2\u003e\r\\n\u003cul data-spread=\"false\"\u003e\r\\n \t\u003cli\u003eContains \u003cstrong\u003eCeftriaxone\u003c\/strong\u003e, a third-generation cephalosporin antibiotic.\u003c\/li\u003e\r\\n \t\u003cli\u003eAvailable in \u003cstrong\u003e500mg and 1g strengths\u003c\/strong\u003e.\u003c\/li\u003e\r\\n \t\u003cli\u003eProvides broad antibacterial activity against many susceptible Gram-positive and Gram-negative bacteria.\u003c\/li\u003e\r\\n \t\u003cli\u003eUsed for serious and clinically significant \u003cstrong\u003ebacterial infections\u003c\/strong\u003e requiring antibiotic treatment.\u003c\/li\u003e\r\\n \t\u003cli\u003eConvenient injectable formulation for hospital and clinical use.\u003c\/li\u003e\r\\n \t\u003cli\u003eThe 500mg and 1g presentations allow physicians to select the appropriate strength according to individual treatment requirements.\u003c\/li\u003e\r\\n \t\u003cli\u003eManufactured by \u003cstrong\u003eSeraph Pharmaceuticals, Pakistan\u003c\/strong\u003e.\u003c\/li\u003e\r\\n\u003c\/ul\u003e\r\\n\u003ch2\u003eHow It Works\u003c\/h2\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eCeftriaxone is a \u003cstrong\u003ethird-generation cephalosporin\u003c\/strong\u003e that works by inhibiting bacterial cell-wall synthesis. It binds to bacterial penicillin-binding proteins and interferes with the formation of a stable bacterial cell wall, resulting in the death of susceptible bacteria.\u003c\/p\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eBecause Ceftriaxone has activity against a broad range of bacteria, it may be selected for various infections when the causative organisms are susceptible and injectable antibiotic treatment is appropriate.\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003eUses \/ Therapeutic Applications\u003c\/h2\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eDRONCEF (Ceftriaxone) may be prescribed by a healthcare professional for susceptible bacterial infections, including certain:\u003c\/p\u003e\r\\n\r\\n\u003cul data-spread=\"false\"\u003e\r\\n \t\u003cli\u003eRespiratory tract infections\u003c\/li\u003e\r\\n \t\u003cli\u003ePneumonia\u003c\/li\u003e\r\\n \t\u003cli\u003eUrinary tract infections\u003c\/li\u003e\r\\n \t\u003cli\u003eSkin and soft-tissue infections\u003c\/li\u003e\r\\n \t\u003cli\u003eIntra-abdominal infections\u003c\/li\u003e\r\\n \t\u003cli\u003eBone and joint infections\u003c\/li\u003e\r\\n \t\u003cli\u003eBloodstream infections\u003c\/li\u003e\r\\n \t\u003cli\u003eCertain sexually transmitted bacterial infections\u003c\/li\u003e\r\\n \t\u003cli\u003eBacterial meningitis\u003c\/li\u003e\r\\n \t\u003cli\u003eOther serious bacterial infections requiring parenteral antibiotic therapy\u003c\/li\u003e\r\\n\u003c\/ul\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eThe exact indication should be determined by the treating physician based on the infection, clinical presentation and, where appropriate, microbiological testing.\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003eDirections for Use\u003c\/h2\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eDRONCEF Injection must be \u003cstrong\u003eprepared and administered by a qualified healthcare professional\u003c\/strong\u003e. The dosage and frequency depend on the patient's age, weight, type and severity of infection and other clinical factors.\u003c\/p\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eThe \u003cstrong\u003e500mg and 1g strengths are not interchangeable without medical direction\u003c\/strong\u003e. Follow the approved product information for reconstitution, dilution, compatibility and administration.\u003c\/p\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eThe supplied 1g pack is specifically labelled \u003cstrong\u003efor IV use\u003c\/strong\u003e. Certain Ceftriaxone products may also be available in IM presentations, but the route should always be confirmed from the specific product pack before administration.\u003c\/p\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eDo not self-inject DRONCEF.\u003c\/strong\u003e\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003ePrecautions\u003c\/h2\u003e\r\\n\u003cul data-spread=\"false\"\u003e\r\\n \t\u003cli\u003eDRONCEF is a \u003cstrong\u003eprescription antibiotic\u003c\/strong\u003e.\u003c\/li\u003e\r\\n \t\u003cli\u003eTell your doctor about previous allergic reactions to \u003cstrong\u003eCeftriaxone, cephalosporins, penicillins or other beta-lactam antibiotics\u003c\/strong\u003e.\u003c\/li\u003e\r\\n \t\u003cli\u003eInform your doctor if you have liver or kidney disease.\u003c\/li\u003e\r\\n \t\u003cli\u003eTell your healthcare professional about all medicines you are taking.\u003c\/li\u003e\r\\n \t\u003cli\u003eCeftriaxone should be used only when bacterial infection is suspected or confirmed and antibiotic therapy is appropriate.\u003c\/li\u003e\r\\n \t\u003cli\u003eAntibiotics are not effective against viral infections such as common cold or influenza.\u003c\/li\u003e\r\\n \t\u003cli\u003eTell your doctor if you have a history of gastrointestinal disease or antibiotic-associated diarrhea.\u003c\/li\u003e\r\\n \t\u003cli\u003eUse during pregnancy or breastfeeding only according to professional medical advice.\u003c\/li\u003e\r\\n \t\u003cli\u003eSeek immediate medical attention for difficulty breathing, facial swelling, severe rash or other signs of a serious allergic reaction.\u003c\/li\u003e\r\\n\u003c\/ul\u003e\r\\n\u003ch2\u003ePossible Side Effects\u003c\/h2\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003ePossible side effects of Ceftriaxone may include \u003cstrong\u003ediarrhea, nausea, vomiting, abdominal discomfort, headache, rash and pain or irritation at the injection site\u003c\/strong\u003e. Changes in liver enzymes or blood counts may also occur.\u003c\/p\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eSerious reactions are uncommon but can include severe allergic reactions, serious skin reactions and antibiotic-associated colitis. Seek medical attention if severe or persistent diarrhea, significant rash, breathing difficulty or other serious symptoms develop.\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003eStorage Instructions\u003c\/h2\u003e\r\\n\u003cul data-spread=\"false\"\u003e\r\\n \t\u003cli\u003eStore according to the manufacturer's recommended storage conditions.\u003c\/li\u003e\r\\n \t\u003cli\u003eKeep the unopened vial in its original packaging.\u003c\/li\u003e\r\\n \t\u003cli\u003eProtect from excessive heat, moisture and direct sunlight.\u003c\/li\u003e\r\\n \t\u003cli\u003eKeep out of reach of children.\u003c\/li\u003e\r\\n \t\u003cli\u003eDo not use after the expiry date.\u003c\/li\u003e\r\\n \t\u003cli\u003eReconstituted solutions should be prepared and stored according to the approved product information and healthcare-facility procedures.\u003c\/li\u003e\r\\n \t\u003cli\u003eInspect the prepared solution before administration.\u003c\/li\u003e\r\\n\u003c\/ul\u003e\r\\n\u003ch2\u003eManufacturer Information\u003c\/h2\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eBrand:\u003c\/strong\u003e DRONCEF\r\\n\u003cstrong\u003eGeneric Name:\u003c\/strong\u003e Ceftriaxone\r\\n\u003cstrong\u003eAvailable Strengths:\u003c\/strong\u003e 500mg \u0026amp; 1g\r\\n\u003cstrong\u003eDosage Form:\u003c\/strong\u003e Powder for Injection\r\\n\u003cstrong\u003eRoute:\u003c\/strong\u003e IV\r\\n\u003cstrong\u003eDrug Class:\u003c\/strong\u003e Third-Generation Cephalosporin Antibiotic\r\\n\u003cstrong\u003eManufacturer:\u003c\/strong\u003e Seraph Pharmaceuticals\r\\n\u003cstrong\u003eCountry:\u003c\/strong\u003e Pakistan\u003c\/p\u003e\r\\n\u003cp class=\"isSelectedEnd\"\u003eDRAP records identify \u003cstrong\u003eDroncef 500mg Injection IV\u003c\/strong\u003e as Ceftriaxone (as sodium) and list Seraph Pharmaceutical as the company. DRAP registration documentation also identifies \u003cstrong\u003eDroncef 1g IV\u003c\/strong\u003e as the reference product for another Ceftriaxone 1g presentation, confirming the 1g Droncef presentation.\u003c\/p\u003e\r\\n\r\\n\u003ch2\u003eProduct Specifications\u003c\/h2\u003e\r\\n\u003ctable\u003e\r\\n\u003ctbody\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eSpecification\u003c\/td\u003e\r\\n\u003ctd\u003eDRONCEF 500mg\u003c\/td\u003e\r\\n\u003ctd\u003eDRONCEF 1g\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eBrand Name\u003c\/td\u003e\r\\n\u003ctd\u003eDRONCEF\u003c\/td\u003e\r\\n\u003ctd\u003eDRONCEF\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eGeneric Name\u003c\/td\u003e\r\\n\u003ctd\u003eCeftriaxone\u003c\/td\u003e\r\\n\u003ctd\u003eCeftriaxone\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eActive Ingredient\u003c\/td\u003e\r\\n\u003ctd\u003eCeftriaxone (as sodium)\u003c\/td\u003e\r\\n\u003ctd\u003eCeftriaxone (as sodium)\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eStrength\u003c\/td\u003e\r\\n\u003ctd\u003e500mg\u003c\/td\u003e\r\\n\u003ctd\u003e1g\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eDosage Form\u003c\/td\u003e\r\\n\u003ctd\u003ePowder for Injection\u003c\/td\u003e\r\\n\u003ctd\u003ePowder for Injection\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eDrug Class\u003c\/td\u003e\r\\n\u003ctd\u003eAntibiotic\u003c\/td\u003e\r\\n\u003ctd\u003eAntibiotic\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003ePharmacological Class\u003c\/td\u003e\r\\n\u003ctd\u003e3rd-Generation Cephalosporin\u003c\/td\u003e\r\\n\u003ctd\u003e3rd-Generation Cephalosporin\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eRoute\u003c\/td\u003e\r\\n\u003ctd\u003eIV\u003c\/td\u003e\r\\n\u003ctd\u003eIV\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eTherapeutic Category\u003c\/td\u003e\r\\n\u003ctd\u003eAntibacterial\u003c\/td\u003e\r\\n\u003ctd\u003eAntibacterial\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eManufacturer\u003c\/td\u003e\r\\n\u003ctd\u003eSeraph Pharmaceuticals\u003c\/td\u003e\r\\n\u003ctd\u003eSeraph Pharmaceuticals\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003eCountry\u003c\/td\u003e\r\\n\u003ctd\u003ePakistan\u003c\/td\u003e\r\\n\u003ctd\u003ePakistan\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003ctr\u003e\r\\n\u003ctd\u003ePrescription Status\u003c\/td\u003e\r\\n\u003ctd\u003ePrescription Medicine\u003c\/td\u003e\r\\n\u003ctd\u003ePrescription Medicine\u003c\/td\u003e\r\\n\u003c\/tr\u003e\r\\n\u003c\/tbody\u003e\r\\n\u003c\/table\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":44164578967611,"sku":null,"price":0.0,"currency_code":"PKR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0695\/4899\/8715\/files\/droncef-500mg-1g-injection-ceftriaxone-pharma-services-group-3984382.jpg?v=1789726871","url":"https:\/\/pharmaservicesgroup.com\/products\/droncef-500mg-1g-injection-ceftriaxone-pharma-services-group","provider":"Pharma Services Distribution","version":"1.0","type":"link"}